Brit plan to spend millions on AI in healthcare draws detractors

Last week the U.K. government announced plans to pour £250 million (around $301.5 million) into a fledgling AI lab run by the National Health Service (NHS). The work is to focus on advancing medical science in various arenas, including cancer care and dementia. This week the skeptics started weighing in.

The Register, the cheeky tech outlet that has offices in London, San Francisco and Sydney, has posted a roundup of criticisms.

“This is a huge amount of money, and there are a lot more deserving things NHS needs,” says a general practitioner.  

“[S]ince it was AI, it got a prominent slot on the grid,” adds a patient-privacy advocate. “There are no details yet—just a mountain of questions that no one is able to answer, as no one has done any of the thinking.”

Unsurprisingly, there’s already pushback to the pushback.

In the article’s comments section, an anonymous opinion-holder says the project seems worth a go.

“Sometimes you just have to take a gamble to see if something works,” says the commenter. “£250M is loose change compared to the overall NHS budget and an absolute bargain if it improves cancer diagnosis and treatment.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

California-based Acutus Medical has said its ongoing agreement to manufacture and distribute left-heart access devices for Medtronic is the company's only source of revenue. 

The scam took place over a period of seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.